Drug Trial Radar · NCT01225562
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Last checked: Nov 20, 2026Latest source record: Jan 25, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
21,379
Actual
Start
Oct 2010
Primary completion
Dec 2014
Study completion Dec 2014
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 21, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 50 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being carried out to see if a new drug called ticagrelor given twice daily in addition to the ASA therapy decreases the frequency of cardiovascular events (e.g., death from heart disease, heart attack, or stroke).
Conditions
- Myocardial Infarction
- Cardiovascular Death
- Atherothrombosis
- Stroke
Interventions
Ticagrelor 90 mgDrug
Oral dose twice a day
Ticagrelor 60 mgDrug
Oral dose twice a day
Ticagrelor PlaceboDrug
Oral dose twice a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Kaplan-Meier Estimate of the Percentage of Patients Who Experienced Cardiovascular Death (CV Death), Myocardial Infarction (MI) or Stroke Within 3 Years From RandomizationTime frame: Randomization up to 47 months
- Kaplan-Meier Estimate of the Percentage of Patients Who Experienced a TIMI Major Bleeding Within 3 Years From First Dose of Study Drug Units: Percentage of PatientsTime frame: First dosing up to 48 months
Locations
826 sites in 31 countries. Site status is shown where the registry gives one.
Research Site
Alexander City, Alabama
Research Site
Athens, Alabama
Research Site
Birmingham, Alabama
Research Site
Huntsville, Alabama
Research Site
Mobile, Alabama
Research Site
Sheffield, Alabama
Research Site
Glendale, Arizona
Research Site
Phoenix, Arizona
Research Site
Jonesboro, Arkansas
Research Site
Little Rock, Arkansas
Research Site
Alhambra, California
Research Site
Anaheim, California
Research Site
Bakersfield, California
Research Site
Fountain Valley, California
Research Site
La Mesa, California
Research Site
Larkspur, California
Research Site
Lomita, California
Research Site
Los Angeles, California
Research Site
Modesto, California
Research Site
Newport Beach, California
Research Site
Oakland, California
Research Site
Oceanside, California
Research Site
San Diego, California
Research Site
San Marino, California
Research Site
Santa Rosa, California
Research Site
Ventura, California
Research Site
Westlake Village, California
Research Site
Aurora, Colorado
Research Site
Colorado Springs, Colorado
Research Site
Littleton, Colorado
Research Site
Loveland, Colorado
Research Site
Hartford, Connecticut
Research Site
Stamford, Connecticut
Research Site
Newark, Delaware
Research Site
Washington D.C., District of Columbia
Research Site
Boca Raton, Florida
Research Site
Clearwater, Florida
Research Site
Coral Springs, Florida
Research Site
Crystal River, Florida
Research Site
Davie, Florida
Showing 40 of 826 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.